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Abstract 
Background: Targeted anti-HER2 therapy has greatly improved the prognosis for many breast cancer patients. How-
ever, treatment for HER2 negative disease is currently still selected from a multitude of untargeted chemotherapeutic 
treatment options. A predictive test was developed using patient-derived spheroids to identify the most effective 
therapy for patients with HER2 negative breast cancer of all stages, for clinically relevant subgroups, as well as indi-
vidual patients.
Methods: Tumor samples from 120 HER2 negative patients obtained through biopsy or surgical excision were 
tested in the breast cancer spheroid model using scaffold-free cell culture. Similarly, spheroids were also generated 
from established HER2 negative breast cancer cell lines T-47D, MCF7, HCC1143, and HCC1937 to compare treatment 
efficacy of heterogeneous cell populations from patient tumor tissue with homogeneous cell lines. Spheroids were 
treated in vitro with guideline-recommended compounds. Treatment mediated impact on cell survival was subse-
quently quantified using an ATP assay.
Results: Differences were observed in the metabolic activity of the untreated spheroids, whereby cell lines consist-
ently achieved higher values compared to tissue spheroids (p < 0.001). A higher number of cells per spheroid corre-
lated with a higher basal metabolic activity in tissue-derived spheroids (p < 0.01), while the opposite was observed for 
cell line spheroids (p < 0.01). Recurrent tumors showed a higher mean vitality (p < 0.01) compared to primary tumors. 
Except for taxanes, treatment efficacy for most tested compounds differed significantly between breast cancer tissue 
spheroids and breast cancer cell lines. Overall a high variability in treatment response in vitro was seen in the tis-
sue spheroids regardless of the tested substances. A greater response to anthracycline/docetaxel was observed for 
hormone receptor negative samples (p < 0.01). A higher response to 5-FU (p < 0.01) and anthracycline (p < 0.05) was 
seen in high grade tumors. Smaller tumor size and negative lymph node status were both associated with a higher 
treatment efficacy to anthracycline treatment combined with 5-FU (cT1/2 vs cT3/4, p = 0.035, cN+ vs cN−, p < 0.05).
Conclusions: The tissue spheroid model reflects current guideline treatment recommendations for HER2 negative 
breast cancer, whereas tested cell lines did not. This model represents a unique diagnostic method to select the most 
effective therapy out of several equivalent treatment options.
Keywords: Breast cancer, Personalized medicine, Preclinical treatment selection, In vitro diagnostics, Spheroid cell 
culture
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Background
Although prognosis has vastly improved for HER2 posi-
tive breast cancer due to targeted anti-HER2 treatment 
options, the remaining majority of patients with HER2 
negative disease lack directed therapy options. For these 
patients a number of guideline directed chemotherapy 
substances and regimen are available. Patients are strati-
fied to a chemotherapy regimen according to routine 
clinicopathological criteria such as TNM-stage, hor-
mone receptor status, grading and tumor histology, as 
well as prior medical history and existing comorbidities 
[1, 2]. This may result in an unfavorable prognosis, espe-
cially for patients not responding to treatment or with 
recurrent, metastatic disease, depending on the publi-
cation recurrence rate of approximately 30 % have been 
reported [3, 4].
Predictive tests or assays to direct cancer treatment 
decisions remain an unmet need in oncology diagnos-
tics and in the field of personalized medicine [5–7]. As of 
today no method to predict chemotherapy outcome for 
individual breast cancer patients is recommended by all 
applicable international authorities for clinical utility [8]. 
Determining treatment success in the adjuvant and met-
astatic treatment setting is a process requiring a lengthy 
follow-up observation period, and a direct association 
is only possible through close surveillance [9, 10]. Clini-
cal prognostic factors at diagnosis according to national 
and international guidelines are age, axillary lymph node 
status, differentiation grade, hormone receptor and/or 
HER2 status, as response to chemotherapy or pathologic 
complete response (pCR) following neoadjuvant chemo-
therapy [11, 12]. Predictive factors for a pCR in neoad-
juvant chemotherapy are high grade (G3) and a negative 
hormone receptor status [13, 14]. Young age at diagnosis 
is associated with both pCR and overall survival [15].
Biomarkers currently being studied in clinical trials 
mostly focus on the molecular profiles which character-
ize the odds of recurrence [16–21]. Depending on the 
individual prognostic risk profile, a recommendation can 
be made if a chemotherapy in general would be beneficial 
or not, however a specific chemotherapy regimen selec-
tion currently cannot be made [22].
Out of the newer techniques such as tumor infiltrat-
ing lymphocytes, Ki-67, circulating tumor cells, genetic 
profiles, and PIK3CA analysis, only the uPA/PAI1 analy-
sis as well as the 21-Gene-Recurrence Score have been 
validated in prospective clinical trials, however, only for 
specific clinical breast cancer subtypes in primary disease 
[22–25].
Laboratory models such as genetically engineered and 
patient-derived xenograft mouse models allow the study 
of deregulated pathways in the development of invasive 
tumors and the treatment efficacy in a living organism 
[26]. However, it has been criticized that these models 
do not accurately mimic tumorigenesis and metastasis 
in humans due to the influence of the murine microenvi-
ronment [27–29]. Other drawbacks of this approach are 
the time consuming and highly care intensive breeding 
and caretaking of these specifically bred immunodefi-
cient mice, and the fact that preclinical drug testing often 
takes months until treatment effects can be determined 
[30, 31]. Another aspect is the cell heterogeneity of the 
human tumor which may not be fully represented in 
murine models [31, 32].
Breast cancer cell lines are another frequently used 
model system and have previously been closely associ-
ated to the originating patient tumors regarding genomic 
aberrations, protein expression even after prolonged cul-
ture, and treatment efficacy [33–35]. However, the het-
erogeneity of all the cell types found in patient tumors 
cannot be replicated using cell lines. A higher level of 
amplification and a differential protein expression pattern 
compared to primary tumor cells has also been observed 
in breast cancer cell lines, one explanation might be the 
source of the cells which is mainly from pleural effusions 
or triple negative primary cancer [36, 37].
One main criticism of standard 2D cell culture is the 
absence of the surrounding cells and microenvironment 
which have an important influence on tumor develop-
ment and progression [35] and drug response [38]. Data 
suggests that these factors can be compensated by using 
3D cell culture models [39]. The 3D culture models that 
are currently being investigated are organotypic explant 
cultures, polarized epithelial cell culture, artificial skin, 
microcarrier culture, and cellular spheroids [40, 41]. 
Although it is also possible to preserve intact human 
tissue in its 3D form such as in organotypic explant cul-
tures, a simplified method is to generate 3D cell spheroids 
from cell lines or primary tumor cells [42, 43]. In com-
parison to 2D monolayer cell culture, the 3D models offer 
the advantage of a more tissue-like complexity and heter-
ogeneity, similar cellular polarity and cellular interactions 
[44, 45]. The 3D architecture also results in the formation 
of a penetration barrier, much like in a patient tumor [46, 
47]. Cancer cells grown in 3D have demonstrated similar 
behavior, structure, and organization compared to in vivo 
tissue [48–50]. In a previous study the spheroid model 
detailed herein has been proven to correctly predict 
treatment outcome for patients undergoing neoadjuvant 
chemotherapy for primary breast cancer [51].
The aim of this study is to determine the treatment effi-
cacy of the most frequently applied treatment options 
on tumor tissue-derived spheroids from HER2 negative 
breast cancer patients. These treatment results were com-
pared to those obtained from established HER2 negative 
breast cancer cell lines, namely MCF7, T-47D, HCC1143, 
Page 3 of 14Halfter et al. J Transl Med  (2016) 14:112 
and HCC1937. Clinical subgroups were analyzed sepa-
rately to determine if groups of patients or individual 
patients could be identified which deviate from the mean 
in regard to treatment efficacy in vitro, thus determining 
new treatment strategies for these patients.
Methods
Patients and study design
The tissue was provided by a representative patient 
cohort of 120 HER2 negative breast cancer patients 
between 2011 and 2015 out of a total of 200 collected. 
Samples were considered in this analysis if patients 
were histologically confirmed HER2 negative (HER2+  , 
n = 45) and a valid assay readout was available (no read-
out, n = 43), a total of 8 samples failed to fulfill both cri-
teria. Tissue samples were consecutively collected either 
through an ultrasound-guided core biopsy procedure 
(n  =  77) or through surgical excision (n  =  43). Tissue 
samples derived from primary (n =  109) and recurrent 
tumors (n = 11). Tissue from the recurrent tumors was 
obtained from local recurrence (n  =  6), lymph nodes 
(n = 2), or distant metastasis (n = 3). Samples from two 
different tumor sites were obtained from five patients, 
in two cases from the originating breast tumor and the 
simultaneous lymph node metastasis, one case of inva-
sive lobular carcinoma obtained from the right and left 
breast, as well as tumor tissue from two different meta-
static sites from two patients. Clinical and pathologi-
cal data is reported from the time of tissue excision. A 
written and oral informed consent was obtained from all 
patients prior to tissue excision, and an approval by all 
applicable ethics committees was obtained prior to study 
start.
Breast cancer spheroid model
All laboratory procedures were performed according to 
standardized, quality-controlled operating procedures. 
The mean cold ischemic time for the surgical samples 
was 22.13  min (range 0–60  min), the time from tis-
sue excision to the beginning of the cell isolation pro-
cedure was mean 24.09  h (range 14.75–48  h). Biopsy 
samples were directly transferred to freshly prepared 
culture medium following excision. Breast cancer sphe-
roids were directly generated from cancerous tissue as 
described recently [51]. Briefly, fresh tumor tissue sam-
ples were mechanically and enzymatically (Roche, Ger-
many) digested to generate a single-cell suspension. Cell 
number and viability of the single-cell suspension were 
determined using the trypan-blue exclusion test (Sigma 
Aldrich, Germany). The isolated cells were combined 
with a scaffold-free cell culture substrate and distrib-
uted evenly on a 96-well plate for subsequent spheroid 
formation.
Cell line spheroids were generated using the repre-
sentative hormone receptor positive breast cancer cell 
lines MCF7 (HTB-22) [52], T-47D (HTB-133) [53], as 
well as the triple negative cell lines HCC1143 (CRL-
2321) [54] and HCC1937 (CRL-2336) [55], all acquired 
from ATCC® (American Type Culture Collection, 
USA). Cells were grown in appropriate culture medium 
and kept in culture for a maximum of 10 passages. For 
spheroid preparation, cells were detached using 1  mM 
EDTA and seeded 0.05 ×  106 per well. All experiments 
were repeated a minimum of three times, and given val-
ues represent a mean of all experiments with exceptions 
specifically detailed. The last passage of all four cell lines 
used in the treatment experiments was sent for external 
STR-analysis for authentication (IDEXX BioResearch, 
Germany). In addition cytospin samples of each cell line 
were prepared and stained using standard immunohisto-
chemistry for confirmation of the epithelial origin, prolif-
eration rate, and receptor status (data not shown).
Both primary tissue and cell line spheroids were kept 
under standard culture conditions (37  °C, 5  % CO2) for 
a consecutive 48  h following seeding. The spheroids 
were then treated with guideline recommended cyto-
static compounds or combination of compounds using 
the peak plasma concentrations as detailed in a previous 
publication [1, 51, 56, 57]. Solvent controls were also run 
with each tissue and cell line experiment. The drug treat-
ment was allowed to incubate for another 96  h. Treat-
ment efficacy was assessed using an ATP assay (Promega, 
Germany) to quantify cell survival in  vitro. Mean cell 
survival was expressed as percent of residual metabolic 
activity relative to the solvent controls. Analysis of tissue 
and cellular characteristics was done using all received 
tissue samples (n = 125), obtained from 120 patients.
Statistics
Data comparison across cell lines and patients was done 
using the Kruskal–Wallis test and subsequent post hoc 
analysis; p-values were adjusted for multiple testing. 
Two-group comparisons were done using the Mann–
Whitney U test. Bivariate correlation was done using the 
Pearson correlation procedure. Results were considered 
significant if the p value was lower than 0.05. All statisti-
cal analysis was done using IBM SPSS Statistics Version 
22. The treatment efficacy heatmap was generated using 
the program R version 3.1.2, module gplots heatmap2.
Results
Patient characteristics
The mean age of the patients was 58 (range 21–85) years 
at sample excision. The majority of tumors were either ER 
and/or PR positive (66.8  %), stage cT1/2 (74.7  %), node 
negative (52.0  %), with a high-grade (50.2  %) invasive 
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ductal/other histology (84.2  %). A mean Ki67 score of 
39.22  % positive cells (range 0.01–100  %) was recorded 
for the collected study samples. Patient characteristics 
are summarized in Table 1.
Comparison of baseline characteristics between tissue 
and cell line spheroids
Mean cell viability of single cell suspensions follow-
ing cell isolation from fresh tumor tissues was 87.0  % 
(range 26.2–100  %). No differences in cellular viability 
was found for cells isolated from biopsy or surgical tis-
sue (mean 87.6 biopsy vs. 85.9 % surgical samples). Dif-
ferences in viability were detected between primary and 
recurrent tumors, the measured viability was higher 
for the recurrent tumor samples (mean 86.1 primary vs 
93.5 % viability recurrent tumors, p < 0.001).
The number of isolated cells was highly dependent 
on the amount of tissue that was provided (p  <  0.001). 
The surgical tissue weighed a mean of 1020.6 mg (range 
58.6–7232.3  mg) and the biopsy samples a mean of 
86.3  mg (range 10.5–513.3  mg). No significant differ-
ence in the number of cells per mg tissue was observed 
between surgical specimen 5201.1  cells/mg (range 
284.5–58949.8 cells/mg) and biopsy samples 6061.0 cells/
mg (range 78.18–84143.6 cells/mg; surgical specimen vs 
biopsy) or between primary (mean 4691.5, range 78.2–
66571.4  cells/mg) and recurrent tumors (mean 14919.0, 
range 433.2–84143.6  cells/mg, primary vs recurrent 
tumors). However, due to the higher total tissue weight, 
a higher number of treatment options could be tested 
using surgical specimen: a mean of 8 (range 1–23) for 
the surgical specimen and 2 treatment options (range 
1–9) for the biopsy samples (surgical vs biopsy samples, 
p  <  0.001). Using regression analysis over all samples, 
it was determined that a minimum of 69 mg of tissue is 
required to test a minimum of three different treatment 
options (p < 0.001).
The amount of ATP quantified for solvent control sam-
ples (counts per second, cps) in the assay was measured 
to determine any differences in metabolic activity not 
associated with cytostatic treatment. Comparison of the 
tissue-derived spheroids revealed differences between 
biopsy and surgical samples in metabolic activity, biopsy 
samples reaching a mean of 0.479  cps/cell compared to 
a mean of 1.055 cps/cell for surgical samples (surgical vs 
biopsy samples, p < 0.01). The mean cps value relative to 
the number of cells per spheroid of the primary tumor 
spheroids was 0.628 cps; recurrent tumors achieved 
higher values with a mean of 1.022 cps, the difference was 
however not statistically significant. Spheroids generated 
from breast cancer cell lines showed much higher meta-
bolic activity values with a mean of 26.55  cps (primary 
tumor samples vs. cell lines, p < 0.001, recurrent tumor 
Table 1 Patient cohort description
Clinical data was collected at the time of tissue accruement. Histological data 
was taken from the pathological examination of the respective biopsy/surgical 
tissue. Hormone receptor status was considered positive if one or both ER 
and PR were found positive according to current guidelines for pathological 
examination, ≥1 % positive cells
ER estrogen receptor, PR progesterone receptor
Characteristics All HER negative 
patients
N %





















Not documented 5 –
Histology
Invasive ductal/other 101 84.2
Invasive lobular 17 15.8















Not documented 1 –
Ki67
Mean (% positive stained cells) 39.22
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samples vs. cell lines, p  <  0.001). The highest values of 
metabolic activity was observed for MCF7 (36.85  cps/
cell), followed by T-47D (32.36  cps/cell), HCC1937 
(28.10 cps/cell), and HCC1143 (3.76 cps/cell), the differ-
ence between the cell lines was not significant.
In order to determine the effect of cell number in tis-
sue-derived spheroids on metabolic activity data was 
collected using <10,000, 10,000–20,000, >20,000 cells 
per spheroid. As shown in Fig.  1, tissue-derived sphe-
roids showed a higher metabolic activity the more cells 
were included per spheroid (p < 0.01). The difference in 
metabolic activity was significant between spheroids 
containing <10,000 (mean 0.256  cps) and >20,000 cells 
(mean 0.973  cps, p  <  0.05). In addition, significant dif-
ferences in metabolic activity were found between sphe-
roids containing 10,000–20,000 cells (mean 0.296  cps) 
and >20,000 cells (mean 0.973 cps, p < 0.01). A correla-
tion of metabolic activity with the absolute number of 
cells per spheroid was also significant, the more cells per 
generated spheroid resulted in a higher metabolic activ-
ity (p  <  0.05). The results for the cell lines MCF7 and 
HCC1937 were inversely effected by the number of cells 
per spheroid: more cells resulted in a lower metabolic 
activity (p  <  0.01). A correlation between cps and the 
proliferation index Ki67 was not detected.
Treatment efficacy in tissue and cell line‑derived spheroids
Collectively, the tissue-derived spheroids showed a high 
variability in response to cytostatic treatment in  vitro, 
regardless of primary or recurrent disease. Individual 
results are shown in Fig. 2. The best efficacy for primary 
tumor cell-derived spheroids was seen with FEC-Doc 
(5-FU  +  Epirubicin  +  Cyclophosphamide–Docetaxel) 
resulting in a mean of 13.62  % cell survival over all 
tested samples (n  =  12), followed by EC-Pac (Epiru-
bicin + Cyclophosphamide–Paclitaxel, 16.63 %, n = 19), 
and DocAC (Docetaxel  +  Doxorubicin  +  Cyclophos-
phamide, 17.37  %, n  =  38, Table  2). Taxane treatment 
had the lowest impact on cell survival with a mean of 
74.98 and 85.95 % for Pac and Doc respectively. Overall, 
combination treatments showed a better response com-
pared to single-agent treatment for both primary and 
recurrent samples, carboplatin (Crbp) showing the best 
response in vitro (primary tumor samples, mean cell sur-
vival 36.97 %, n = 13, recurrent tumor samples, 31.07 %, 
n  =  5). Generally the samples from recurrent tumors 
responded better to treatment in  vitro as compared to 
samples from the primary tumors, although the differ-
ences were not statistically significant. For the recurrent 
tumor samples the best results were seen for treatment 
with EC-Pac (3.89 %, n = 2). 
Data shown in Fig. 2 demonstrated that cell line sphe-
roids showed a consistently lesser cytostatic response 
than tissue spheroids. Exception was the taxane treat-
ment, with Doc and Pac showing similar efficacy in both 
tissue and cell line spheroids. Individual treatment effi-
cacy data for all cell lines is shown in Table 3.
Treatment efficacy for clinically relevant subgroups
In order to better identify patient subgroups responding 
best to individual treatment regimen, the results from the 
patient-derived spheroids were grouped according to the 
clinical factors reported in Table 1.
As shown in Table  2, smaller tumors responded bet-
ter to treatment with FEC (cT1/2, n  =  18, 16.69  % vs. 
cT3/4, n =  11, 37.01 % mean cell survival, p < 0.05), as 
well as FEC-Doc (cT1/2, n = 4, 3.44 % vs. cT3/4, n = 4, 
14.97  % mean cell survival, p  <  0.05). Similarly, a nega-
tive lymph node status was also associated with a better 
response to FEC (cN-, n = 17, 17.28 % vs. cN+ , n = 12, 
34.94 % mean cell survival, p < 0.05). Grading was found 
to be significantly associated with EC treatment effi-
cacy (p  <  0.05), whereby G3 tumors (n  =  29, 28.39  % 
mean cell survival) responded better than G1/2 tumors 
(n = 41, 42.15 % mean cell survival). A similar association 
was observed for the treatment with 5-FU (G3, n = 10, 
32.37 % vs. G1/2, n =  8, 63.56, p < 0.01). The hormone 
negative subgroup showed higher treatment efficacy in 
response to EC-Doc (n  =  7, 8.63  % mean cell survival, 
p  <  0.01) and DocAC (n  =  19, 9.14  %, p  <  0.05) com-
pared to the hormone receptor positive tumors [EC-Doc 
(n = 20, 27.82 % mean cell survival) and DocAC (n = 22, 
23.18 %)]. Analysis of drug response in regard to the ER 
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Fig. 1 Metabolic activity of the spheroids (cps) measured after incu-
bation with solvent control grouped according to cell number per 
spheroid. Filled circle primary tumor, filled gray circle recurrent tumor 
samples, open triangle cell lines, line mean, *p < 0.05, **p < 0.001. cps 
counts per second
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between positive and negative samples and remained 
robust for EC-Doc, not however for DocAC and EC 
although high differences in cell survival were evident. 
However, a total of 10 samples were ER+/PR− while only 
one sample was ER−/PR+. Differences in drug response 
were therefore observed in regard to EC and PR status: 
PR negative samples showed a higher response (n = 28, 
28.64 % mean cell survival) compared to PR positive sam-
ples (n = 47, 40.54 %; p < 0.05). A difference in cytostatic 
efficacy in  vitro was not detected between core needle 
and surgical tissue samples regardless of the tested sub-
stance. Age, nodal status, metastatic disease, Ki67, and 
tumor histology did not show a significant association 
with treatment response on tissue spheroids.
Treatment efficacy to Doc was greater with higher met-
abolic activity (p < 0.05). For all other tested compounds 
no significant correlation between these two factors was 
found. However, an effect was seen when comparing 
treatment efficacy with a metabolic activity above and 
below the observed median of 0.169  cps/cell (Table  2). 
Treatment efficacy was higher for samples with a meta-
bolic activity above the median, the effect was seen for 
EC-Doc (>0.169  cps/cell, n =  16, 11.40 vs. ≤0.169  cps/
cell, n = 9, 34.70 % mean cell survival, p < 0.01), EC-Pac 
(>0.169 cps/cell, n = 13, 9.17 vs. ≤0.169 cps/cell, n = 4, 
18.35 % mean cell survival, p < 0.05), DocAC (>0.169 cps/
cell, n  =  24, 9.19 vs.  ≤0.169 cps/cell, n  =  16, 24.03  % 
mean cell survival, p < 0.01), as well as FEC (>0.169 cps/
cell, n =  21, 17.09 vs. ≤0.169  cps/cell, n =  17, 32.08  % 
mean cell survival, p < 0.05).
Contrary data was found for the cell lines, both hor-
mone receptor positive/low grade cell lines consistently 
responding better to treatment in  vitro. This effect was 
seen for Doc (HR+/low-grade, 80.33  % vs. HR−/high-
grade, 114.70  %, p  <  0.05), EC-Pac (HR+/low-grade, 
54.98  %, HR−/high-grade, 88.23  %, p  <  0.05), DocAC 
(HR+/low-grade, 64.89 % vs. HR−/high-grade, 90.06 %, 
p  =  0.028), and EC-Doc (HR+/low-grade, 80.09  % vs. 
HR−/high-grade, 104.39 %, p < 0.05).
A grouped comparison of receptor positive or nega-
tive tissue with the respective HR+ or HR− cell line 
spheroids showed no difference in the treatment with 
taxanes. However, for all other tested compounds drug 
efficacy was significantly higher in tissue spheroids 
regardless of hormone receptor status. Exception was 











































Fig. 2 Dot plot grouped according to tested chemotherapy. Filled circle primary tumor, filled gray circle recurrent tumor samples, open triangle cell 
lines, black line mean T tissue, C cell lines. 5-FU 5-fluorouracil, Crbp carboplatin, Doc docetaxel, Pac paclitaxel, EC epirubicin + cyclophosphamide, 
DocAC docetaxel + doxorubicin + cyclophosphamide, FEC 5-fluorouracil + epirubicin + cyclophosphamide
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response in HR− tissue spheroids compared to HR− cell 
line spheroids (p < 0.05). Grouped comparison according 
to grading revealed tissue spheroids responding much 
better to treatment compared to the respective cell line 
spheroids with the same grading. Taxane treatment was 
not significantly more effective for either high- or low-
grade tissue spheroids versus cell lines. Again, 5-FU 
was only significantly more effective for high-grade tis-
sue spheroids compared to the matched cell lines (G3, 
p < 0.05).
Table 2 Treatment efficacy represented as cell survival relative to the respective solvent control
5-FU Crbp Doc Pac EC EC-D EC-P DocAC FEC FEC-D
Tissue 
Biopsy 37.21 35.84 88.12 74.02 36.77 26.34 12.20 21.19 24.36 nd
Surgical 46.68 35.23 83.99 75.42 35.99 20.50 15.94 12.62 22.73 13.18
Disease Primary 52.01 36.97 87.20 75.89 36.50 23.51 16.63 17.37 25.32 13.62
Recurrent 41.51 31.07 78.11 72.05 31.49 5.51 3.89 7.89 13.10 22.63
Age [y] < 50 55.99 29.61 88.89 75.28 39.91 19.00 18.79 8.59 19.71 14.00
≥ 50 43.41 39.90 84.40 74.68 33.95 23.72 13.73 18.95 25.80 13.82
cT stage
cT1/2 42.73 36.69 86.52 79.54 35.51 16.23 12.03 10.50 16.69* 3.44*
cT3/4 51.73 37.37 88.09 72.22 34.47 26.43 15.70 24.80 37.01 14.97
cN stage cN+ 42.35 29.05 82.57 69.77 39.47 24.02 13.36 14.92 34.94* 1.98
cN- 37.19 30.80 92.18 74.93 34.04 13.92 9.37 13.42 17.28 5.46
cM stage M0 44.82 31.51 85.13 73.57 34.27 22.75 14.51 16.29 25.02 12.27
M1 50.80 41.32 84.92 77.27 30.78 23.40 19.28 19.45 16.60 22.63
Histology Ductal/other 46.66 30.98 86.99 71.25 37.54 23.84 15.42 16.44 25.53 14.80
Lobular 50.74 45.16 80.22 85.39 30.36 18.46 15.39 18.16 18.87 12.37
Grading G1/2 63.56** 48.20 82.71 77.88 42.15* 27.30 18.97 18.09 24.88 15.00
G3 32.37 25.46 88.56 75.94 28.39 17.28 10.67 16.04 23.88 12.05
HR HR+ 54.21 43.00 82.95 75.36 39.19 27.82** 18.93 23.18* 23.68 17.54
HR- 38.21 27.66 90.35 74.19 29.11 8.63 10.73 9.14 25.53 5.59
ER
Positiv 54.21 43.00 82.95 75.36 39.19 27.82** 18.93 23.65* 23.68 17.54
Negativ 37.79 27.66 90.35 74.19 29.11 8.63 10.73 9.35 25.53 5.59
PR
Positiv 54.75 41.57 83.13 75.93 40.54* 28.85* 18.93 23.63 24.46 17.54
Negativ 39.34 30.33 88.71 73.69 28.64 10.84 10.73 10.73 24.23 5.59
cps/cell 
(median)
≤ 0.169 42.07 36.16 80.32 65.55 41.30 34.70** 18.35* 24.03** 32.08* 14.35
> 0.169 40.81 26.04 88.86 75.89 33.18 11.40 9.17 9.19 17.09 8.72
Mean 47.81 35.33 85.95 74.98 36.46 21.71 14.92 16.29 23.30 13.18
N 20 18 59 35 77 29 22 42 40 14
Mean values are shown in the breast cancer spheroid model for patient samples grouped according to clinical criteria, primary and recurrent tumors are included
Significant differences between clinical subgroups in treatment efficacy are highlighted in dark grey with bold font
* p < 0.05, ** p < 0.001
HR hormone receptor, ER estrogen receptor, PR progesterone receptor, cps counts per second, 5-FU 5-fluorouracil, Crbp carboplatin, Doc docetaxel, Pac paclitaxel, EC 
epirubicin + cyclophosphamide, DocAC docetaxel + doxorubicin + cyclophosphamide, FEC 5-fluorouracil + epirubicin + cyclophosphamide, nd not done





















































































































































































































































































































































































































































































































































Page 9 of 14Halfter et al. J Transl Med  (2016) 14:112 
Treatment efficacy on an individual patient basis
An overview of the assay data from all tested patients 
is shown in Fig. 3: red colored boxes show a poor (over 
70 %), black a mean (from 35 to 70 %) and green a posi-
tive response to chemotherapy in vitro (below 35 %). The 
cutoff at 35  % was established in a previous study [51] 
and was therefore used again in this analysis; a mean cell 
survival above 70 % was considered resistant to cytostatic 
treatment in vitro and used as a second cutoff. The clus-
tering of the data showed that taxanes as single-agents are 
the least effective anti-cancer drugs with only 2 out of 59 
(3.4 %) for Doc and 1 out of 35 (2.9 %) for Pac achieving 
cell survival below 35  %. Also anthracyclines combined 
with taxanes are the most effective with 92.9 % of samples 
tested with FEC-Doc, 86.4  % with EC-Pac, 86.2  % with 
EC-Doc, and 85.7 % with DocAC reaching values below 
35 % cell survival. The addition of 5-FU to the anthracy-
cline-taxane combination therapy adds little benefit with 
77.5 % of tested samples with FEC and 57.1 % of samples 
treated with EC showing a high response. Heterogeneous 
results were seen for Crbp treatment, out of the tested 18 
samples only 8 (44.4 %) showed a high response in vitro.
Detailed treatment options were further tested with 
spheroids generated from five different patients with dis-
seminated tumors (Fig. 4). Results included comparison 
of drug efficacy of spheroids generated from primary 
tumors, simultaneous lymph node metastases and other 
metastatic sites, including peritoneal cavity, neck and 
shoulder, as well as one case of a bilateral tumor. As can 
be seen in these examples the different tumor locations 
obtained from an individual patient each show a differ-
ential response to in  vitro treatment. Compared to the 
primary tumor, the lymph node showed a much better 
response in both of the tested patient samples. Similarly 
to the results seen over all patients, anthracycline-based 
treatment was most effective while taxane single com-
pound treatment was not. Combined anthracycline-
taxane treatment added to the cytostatic effect in  vitro, 
although only slightly in both cases and respective tumor 
sites. The results from the different metastatic sites are 
not as consistent, the two metastatic sites within the per-
itoneal cavity showed similar treatment efficacy whereas 
the two locations from neck and shoulder did not. Due 
to the difference in tissue amount available not all treat-
ment options could be tested. Treatment with EC showed 
the largest effect for the peritoneal metastasis while Crbp 
was most effective for the shoulder and neck metasta-
sis. In the latter case a high discrepancy was seen in the 
response to Pac between the two metastatic sites, no 
cytostatic effect was observed for the shoulder metasta-
sis while the tumor sample taken from the neck showed a 
marked response in vitro. The simultaneous tumors from 
the right and left breast also responded differently, the 
tumor from the left breast showing a higher treatment 
efficacy to all of the tested substances. Although stand-
ard deviation of the samples was very high, again the best 
response was seen for anthracycline-taxane treatment 
while Crbp showed the greatest effect of the single-com-
pounds tested.
Discussion
In this study, tissue-derived spheroids from HER2 nega-
tive patients were studied to determine differences in 
the observed treatment efficacy for the most frequently 
applied treatment schemes in the primary, recurrent, and 



















































































































Fig. 3 Heatmap comparing treatment efficacy for all individual 
patient samples where more than one drug/drug combination was 
tested. Red colored boxes show a poor (over 70 %), black a mean (from 
35 to 70 %) and green a positive response to the applied chemo-
therapy in vitro (below 35 %). Simultaneous samples from one patient 
and different locations are indicated by additional letters. PT primary 
tumor, LN lymph node metastasis, L left, R, right, A, B, different meta-
static sites
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spheroids generated from HER2 negative breast cancer 
cell lines.
Regardless of the tested compound(s) and clinical char-
acteristics, the range in treatment response for patient 
tissue-derived spheroids was highly heterogeneous. 
However, the mean values are representative of current 
international guideline recommendations [1, 56, 57]. 
Similarly, the association with clinically relevant sub-
groups with treatment efficacy in vitro reflects data found 
in largescale clinical trials or meta-analyses which favor 
an anthracycline-taxane based chemotherapy for HER2 
negative patients. The addition of 5-FU to this combi-
nation has previously been found unbeneficial through 
large patient cohort analysis [58], this was also seen in 
Doc Pac EC EC-D EC-P FEC FEC-D FEC-P































5-FU Crbp Pac EC-D EC-P DocAC FEC-D
Fig. 4 Individual patient cases where two tumor locations were compared according to in vitro treatment efficacy in the breast cancer spheroid 
model. a, b Patients number 5115 and 5241, comparison between simultaneous tumor of the breast (PT, white) and lymph node metastasis (LN, 
gray). c, d Show patients number 5191 and 5406, comparison of two different metastatic lesions in two cases of recurrent disease. c Shows two dif-
ferent metastasis of the peritoneal cavity, d were two metastatic lesions from the neck (white bars) and the shoulder (gray). e Shows patient number 
5398, response pattern for a bilateral tumor in the right (white bars) and left (gray) breast
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the tissue spheroids tested in  vitro. Comparison of the 
tested single compound agents showed that carboplatin 
was the most effective while 5-FU and both tested taxan 
compounds only had a small effect. Although the taxanes 
combined with an anthracycline were highly effective, 
similar to the high treatment success seen in the clinical 
application of this treatment combination.
Comparing the results obtained from tissue-derived 
spheroids according to hormone receptor status showed 
that a higher treatment efficacy to anthracycline-taxan 
combination treatment was found for hormone recep-
tor negative tissue samples. This difference in response 
confirm results published by Kaufmann et al. [59] which 
also showed a similar in vitro resistance to Adriamycin 
for HR− primary breast cell culture. Interestingly, tis-
sue spheroids recapitulate clinical findings that a triple 
negative tumor biology is associated with a high rate of 
pCR after chemotherapy [60]. An implicated mecha-
nism for these observations was published recently by 
Lahsaee et  al. [61]. Here, a reduced PRP4  K expres-
sion of the estrogen signaling pathway correlated with 
a reduced response to paclitaxel treatment. Similarly, 
high grade tissue spheroids consistently responded 
better to the anthracycline treatment. Surprisingly, 
treatment with 5-FU-based single- or combination 
treatment was found to be more effective for high-grade 
tissue samples, as well as to smaller tumors and node-
negative patients. As mentioned above the use of 5-FU 
is under discussion, however distinct patient subgroups 
may profit from the application of this drug as an alter-
native to a taxane.
Other differences found in treatment efficacy between 
clinical subgroups were not statistically significant, 
mainly due to the large range in the collected data and 
the small sample size for individual subgroups. A fact 
reflecting this high heterogeneity in the treatment effi-
cacy found for the tissue spheroids is that each patient 
tumor showed a distinct response pattern as seen in the 
heat map in Fig. 3, regardless of the tested treatment and 
clinical characteristics. Although it can be seen that indi-
vidual patients did not follow this distinct pattern, here, 
other treatment combinations would have been more 
effective. Using this approach avoidable side effects might 
be prevented where two equivalent therapy options are 
identified, thus maximizing efficacy and minimizing 
toxicity. A similar effect was also found in two cases of 
primary breast tumor and the simultaneous lymph node 
metastases, two cases of separate metastatic sites and one 
case of bilateral lobular cancer despite having identical 
histopathological characteristics. The spheroids derived 
from the lymph node metastasis showed an overall bet-
ter response to treatment than the primary tumor in both 
cases.
In general, cell line spheroids were consistently more 
resistant to in vitro treatment compared to tissue-derived 
spheroids. Treatment efficacy data was similar to other 
data previously reported in 3D cell culture [62, 63]. The 
differences between the two groups were apparent for 
most tested substances and combinations. Comparison 
of treatment efficacy according to hormone receptor 
status and grading showed contrary results to the tissue-
derived spheroids, low grade and hormone receptor posi-
tive cell line spheroids responding better to cytostatic 
treatment in  vitro. Reasons for this disparity might be 
that efficacy data from the breast cancer cell lines repre-
sent only a small range in the observed treatment efficacy 
found for the tissue-derived spheroids. This contrasting 
data might be due in part to the observed differences in 
baseline metabolic activity. The cell line spheroids show-
ing contrary effects in regard to an increase in the num-
ber of cells per spheroid compared to tissue-derived 
spheroids. Another aspect might be the tissue compo-
sition: patient tissue-derived spheroids contain several 
different cell types not present in the cell line spheroids. 
Also it was observed that some cell lines do not show 
consistent results as reflected by high standard deviations 
for HCC1143 (Table  3), demonstrating that not all cell 
lines may be used as a standardized reproducible model.
Regarding the tissue-derived spheroids, the observed 
between patient, as well as intrapatient heterogeneity 
between tumor locations show the necessity for a more 
individualized treatment algorithm or diagnostic assay. 
The question remains for the ideal model to test treat-
ment efficacy, currently no method is without its draw-
backs, and however it is important to consider all aspects 
of tumor biology, as well as the tumor microenviron-
ment [64, 65]. Current research on predictive biomark-
ers for breast cancer focuses mainly on a molecular and 
genomic characterization of patient tumors. Promising 
results have also been found in immunological biomark-
ers [66, 67]. However, although several biomarker studies 
have been conducted successfully using genetic or molec-
ular analysis to predict treatment outcome, this approach 
has only been successfully validated for clinical routine in 
estrogen receptor positive, lymph node negative breast 
cancer patients [68–70]. Only these two methods were 
able to successfully add clinical predictive data to the 
established clinical characteristics [71]. Other predictive 
models each do not sufficiently represent the individual 
patient either through the influence of a murine micro-
environment or through the insufficient representation 
of the patient tumor characteristics in  vitro. The breast 
cancer spheroid model is representative in the 3D tumor 
heterogeneity and microenvironment and has been suc-
cessfully associated with clinical treatment outcome in a 
previous study. An association between the data obtained 
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through the breast cancer spheroid model and clinical 
treatment outcome i.e. pCR was observed [51]. In this 
analysis, tissue-derived spheroids from HER2 negative 
patients of all stages were studied to determine if any 
differences could be observed in regard to clinical sub-
groups and treatment response. This patient subgroup 
is currently still lacking directed treatment options and 
treatment outcome, and prognosis has not improved for 
this subgroup despite great achievements in tumor biol-
ogy research and molecular characterization [72, 73].
Currently further data is necessary to determine an 
association with prognostic factors regarding survival 
and an additional interventional study to determine the 
independent prognostic and predictive power of the 
breast cancer spheroid model. Data obtained through 
these additional studies may aid in bridging the gap 
between guideline-directed treatment recommendations 
and tumor-directed therapeutic needs using a more rep-
resentative in vitro model.
Conclusion
The current study was conducted to provide additional 
data to validate the breast cancer spheroid model and its 
predictive potential regarding clinical treatment outcome 
for HER2 negative breast cancer patients. Tissue-derived 
spheroids treated in  vitro with guideline recommended 
cytostatic drugs and drug combinations recapitulate 
clinical findings for HER2 negative patients. These find-
ings are in stark contrast to HER2 negative breast cancer 
cell lines suggesting an impact of the stromal microenvi-
ronment in drug response. Taken together, comparison 
between tissue spheroids and cell line spheroids under-
lines that the tissue-derived breast cancer spheroid 
model has the advantage of representing the individual 
patient tumor much more closely in comparison to estab-
lished breast cancer cell lines and may be more suited for 
preclinical drug testing.
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